<DOC>
	<DOCNO>NCT00670046</DOCNO>
	<brief_summary>RATIONALE : Valproic acid may stop growth tumor cell block enzymes need cell growth . It yet know whether valproic acid effective observation treat patient prostate cancer . PURPOSE : This randomized phase II trial study well valproic acid work treat patient progressive , non-metastatic prostate cancer .</brief_summary>
	<brief_title>Valproic Acid Treating Patients With Progressive , Non-Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess whether treatment valproic acid ( type I histone deacetylase inhibitor ) alter kinetics prostate-specific antigen ( PSA ) progression patient non-metastatic prostate cancer biochemical progression . Secondary - Determine duration PSA response . - Assess percentage patient achieve complete response . - Assess percentage patient achieve partial response . - Assess quality life patient . OUTLINE : This multicenter study . Patients randomize 1 2 arm . - Arm I ( observation ) : Patients undergo observation accord standard care . - Arm II ( valproic acid ) : Patients receive oral valproic acid twice daily 1 year absence disease progression unacceptable toxicity . Patients complete quality life questionnaire baseline , 6 month , 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer Asymptomatic , nonmetastatic disease Biochemical progression definitive local therapy ( radical prostatectomy ) Most recent prostatespecific antigen ( PSA ) level ≥ 1.0 ng/mL AND rise prior value No clinical radiological evidence local progression PSA doubling time ( DT ) &lt; 10 month local therapy ( patient receive prior hormone therapy ) At least three PSA value ( least 4 week apart ) require calculate PSADT No clinical radiological evidence metastatic disease , include bone metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month Total bilirubin normal AST/ALT &lt; 2.5 time upper limit normal Creatinine ≤ 2.5 mg/dL Platelet count &gt; 125,000/mm^3 PT aPTT ≤ 1.3 time standard reference Albumin ≥ 3.5 g/dL Geographically accessible willing participate stage study treatment No active second malignancy No known HIV positivity No active , uncontrolled infection ( e.g. , hepatitis A , B , C infection ) No history allergic reaction attribute compound similar chemical biological composition valproic acid No debilitate medical psychiatric illness would preclude give informed consent receive optimal study treatment followup No history hepatic disease significant hepatic dysfunction No history pancreatitis No history seizure disorder clinically treat bipolar disorder PRIOR CONCURRENT THERAPY : More 6 month since prior hormone therapy No prior valproic acid At least 2 week since prior drug specifically know interact valproic acid include , limited , aspirin , felbamate , rifampin , amitriptyline/nortriptyline , carbamazepine , clonazepam , diazepam , ethosuximide , lamotrigine , phenobarbital , primidone , phenytoin , tolbutamide , warfarin , zidovudine No concurrent systemic chemotherapy prostate cancer No concurrent investigational drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>